RxDoctor Payments Data

Paul Royer, MD

Family Medicine · Charles City, IANPI 1932191103

Payments from drug & device makers

$506in general payments, 2019–2025

Across 33 payments — averaging $15.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$114
  • Pfizer$81
  • AbbVie$79
  • Novartis$43
  • Lilly USA, LLC$34
  • Novo Nordisk$27
  • plus $129 from 8 others

What the payments were for

  • Food & beverage$48696%
  • Education$214%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$506 in reported general payments places this provider in the 70th percentile of 1,357 family medicine providers in Iowa.

See all family medicine providers in Iowa

Medicare billing

Part B allowed, 2024
$20,343
Medicare patients
75
Services billed
260

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban247$166,429
OzempicSemaglutide104$114,867
XareltoRivaroxaban115$52,433
FarxigaDapagliflozin Propanediol51$29,611
JanuviaSitagliptin Phosphate16$27,202
TrulicityDulaglutide25$24,019
JardianceEmpagliflozin13$20,923
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog48$19,434
AbrysvoRsv Vacc, Pref A And Pref B/Pf64$19,182
Fentanyl117$13,447
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr20$11,857
Fiasp FlextouchInsulin Aspart (Niacinamide)18$11,538
Breo ElliptaFluticasone/Vilanterol20$10,589
VraylarCariprazine Hcl12$8,601
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$6,524

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Abrysvo$81$185,611311 claims
Novo NordiskOzempic$27$114,867104 claims
Johnson & JohnsonXarelto$25$52,433115 claims
AstraZenecaFarxiga$114$29,61151 claims
GSKAnoro Ellipta, Breo Ellipta, Trelegy Ellipta$12$28,97051 claims
Lilly USA, LLCTrulicity$34$24,01925 claims
AbbVieVraylar$79$8,60112 claims
Astellas Pharma US IncMyrbetriq$14$5,94912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,357 family medicine providers in Iowa.

Other family medicine in Charles City

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →